I work at the interface between emerging and innovative technology, high-growth markets, and compelling product value. Whether in biotechnology or in semiconductors, my goal is achieve a uniquely differentiated value proposition through a strong scientific and engineering basis. This requires an integrated approach to research and development, corporate finance, and intellectual property.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

I have worked with more than fifty companies, both private and public, and at all stages of growth, including:




Aviron   Bios Group   Calipers Lifescience
Aviron (acquired by MedImmune)   Bios Group LP (acquired by Nutech)   Caliper Lifescience
         
Cisco Systems   Cor   Darpa
Cisco Systems   Cor (acquired by Millenium)   Darpa
         
  Exploratorium   GBN
Ernst & Young   Exploratorium   GBN (acquired by Monitor)
         
Genencor   Genentech   Hewlett Packard
Genencor (acquired by Danisco)   Genentech   Hewlett Packard
         
maxygen   MDS  
Maxygen   MDS
  Millenium (acquired by Takeda)
         
  Sandia Labs   SRI International
Monitor   Sandia Labs   SRI International
         
Symyx   Watson Parmaceuticals  
Symyx   Watson Pharmaceuticals   Xenogen (acquired by Caliper)